Is First Trust SMID Growth Strength ETF (FSGS) a Buy, Sell, or Hold?
NASDAQ : FSGS
First Trust SMID Growth Strength ETF — News
$33.5 USD
$0.5 (1.52%)
- Volume
- 140.94
- Average Volume
- 2.47K
- Market Capitalization
- $31.82M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $33.52
- Year Low
- $28.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
| Source | Headline |
|---|---|
|
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaborat gurufocus.com - 2026-07-08 01:00:00 |
|
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
HONG KONG, June 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreemen gurufocus.com - 2026-06-04 00:00:00 |
|
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines f gurufocus.com - 2026-06-02 08:00:00 |
